Sandoz Receives Canadian Approval for Generic Version of Novo Nordisk's Ozempic

Sandoz Group (SIX:SDZ) has received regulatory approval in Canada for its generic version of semaglutide, the active ingredient in Novo Nordisk's widely used diabetes medication, Ozempic. The approval from Health Canada marks a significant step for the generic drugmaker in entering the lucrative market for GLP-1 agonists.

Details of the Approval

Sandoz announced on Friday that Health Canada authorized its generic semaglutide for the treatment of adult patients with type 2 diabetes mellitus. This approval allows the Swiss company to compete directly with Novo Nordisk's (CSE:NOVO-B) brand-name drug in the Canadian market.

The company noted that nearly six million Canadians are living with diabetes, with type 2 diabetes accounting for the vast majority of cases. Sandoz estimates the total value of the GLP-1 market in Canada to be $2.6 billion.

Financial Outlook

Despite the regulatory milestone, Sandoz stated that it does not anticipate any material earnings contribution this year from potential launches of its generic semaglutide. The company confirmed that the Canadian approval does not alter its financial guidance for 2026.

Ad

This indicates that while the approval opens a significant long-term market opportunity, the commercial rollout and subsequent revenue impact are not expected to be immediate. Investors will be watching for the company's launch strategy and timeline.

Broader GLP-1 Strategy

The Canadian approval follows a similar regulatory win for Sandoz earlier in 2026, when it obtained approval for a GLP-1 product in Brazil. The company plans to commercialize that semaglutide generic, named Owozy, in partnership with Adalvo.

These moves highlight Sandoz's broader corporate strategy to establish a foothold in the rapidly growing global market for GLP-1 therapies, which are used for treating both diabetes and obesity.